MARAVAI LIFESCIENCES HLDGS-A (MRVI) Fundamental Analysis & Valuation

NASDAQ:MRVI • US56600D1072

Current stock price

2.98 USD
-0.05 (-1.65%)
At close:
2.98 USD
0 (0%)
After Hours:

This MRVI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MRVI Profitability Analysis

1.1 Basic Checks

  • In the past year MRVI has reported negative net income.
  • In the past year MRVI has reported a negative cash flow from operations.
  • In multiple years MRVI reported negative net income over the last 5 years.
  • MRVI had a positive operating cash flow in 4 of the past 5 years.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -16.97%, MRVI is doing worse than 64.91% of the companies in the same industry.
  • With a Return On Equity value of -61.58%, MRVI is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -16.97%
ROE -61.58%
ROIC N/A
ROA(3y)-13.11%
ROA(5y)-4.04%
ROE(3y)-44.89%
ROE(5y)-7.32%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • MRVI's Gross Margin of 18.30% is on the low side compared to the rest of the industry. MRVI is outperformed by 85.96% of its industry peers.
  • In the last couple of years the Gross Margin of MRVI has declined.
  • The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-39.06%
GM growth 5Y-23.95%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MRVI Health Analysis

2.1 Basic Checks

  • MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MRVI has more shares outstanding than it did 1 year ago.
  • MRVI has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRVI is higher compared to a year ago.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 0.92, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
  • MRVI's Altman-Z score of 0.92 is in line compared to the rest of the industry. MRVI outperforms 40.35% of its industry peers.
  • MRVI has a Debt/Equity ratio of 1.49. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.49, MRVI is not doing good in the industry: 80.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Altman-Z 0.92
ROIC/WACCN/A
WACC11.07%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • MRVI has a Current Ratio of 6.60. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
  • MRVI's Current ratio of 6.60 is amongst the best of the industry. MRVI outperforms 87.72% of its industry peers.
  • A Quick Ratio of 5.69 indicates that MRVI has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.69, MRVI belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.6
Quick Ratio 5.69
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MRVI Growth Analysis

3.1 Past

  • MRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -180.00%.
  • Looking at the last year, MRVI shows a very negative growth in Revenue. The Revenue has decreased by -28.34% in the last year.
  • MRVI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.15% yearly.
EPS 1Y (TTM)-180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-28.34%
Revenue growth 3Y-40.53%
Revenue growth 5Y-8.15%
Sales Q2Q%-11.83%

3.2 Future

  • Based on estimates for the next years, MRVI will show a small growth in Earnings Per Share. The EPS will grow by 7.77% on average per year.
  • Based on estimates for the next years, MRVI will show a quite strong growth in Revenue. The Revenue will grow by 8.13% on average per year.
EPS Next Y33.57%
EPS Next 2Y21.89%
EPS Next 3Y18.43%
EPS Next 5Y7.77%
Revenue Next Year10.72%
Revenue Next 2Y9.3%
Revenue Next 3Y8.68%
Revenue Next 5Y8.13%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRVI Valuation Analysis

4.1 Price/Earnings Ratio

  • MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • MRVI's earnings are expected to grow with 18.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.89%
EPS Next 3Y18.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRVI Dividend Analysis

5.1 Amount

  • No dividends for MRVI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRVI Fundamentals: All Metrics, Ratios and Statistics

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (3/20/2026, 8:11:15 PM)

After market: 2.98 0 (0%)

2.98

-0.05 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-25
Earnings (Next)05-11
Inst Owners77.02%
Inst Owner Change-3.53%
Ins Owners5.25%
Ins Owner Change-0.28%
Market Cap766.07M
Revenue(TTM)185.74M
Net Income(TTM)-130.77M
Analysts76.47
Price Target4.01 (34.56%)
Short Float %9.75%
Short Ratio8.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.31%
Min EPS beat(2)3.93%
Max EPS beat(2)44.7%
EPS beat(4)2
Avg EPS beat(4)7.05%
Min EPS beat(4)-10.61%
Max EPS beat(4)44.7%
EPS beat(8)3
Avg EPS beat(8)-31.35%
EPS beat(12)4
Avg EPS beat(12)-36.74%
EPS beat(16)8
Avg EPS beat(16)-24.59%
Revenue beat(2)0
Avg Revenue beat(2)-8.52%
Min Revenue beat(2)-16.71%
Max Revenue beat(2)-0.32%
Revenue beat(4)1
Avg Revenue beat(4)-3.64%
Min Revenue beat(4)-16.71%
Max Revenue beat(4)4.37%
Revenue beat(8)3
Avg Revenue beat(8)-2.36%
Revenue beat(12)4
Avg Revenue beat(12)-2.25%
Revenue beat(16)6
Avg Revenue beat(16)-1.74%
PT rev (1m)0%
PT rev (3m)1.85%
EPS NQ rev (1m)19.14%
EPS NQ rev (3m)11.85%
EPS NY rev (1m)13.54%
EPS NY rev (3m)12.4%
Revenue NQ rev (1m)4.24%
Revenue NQ rev (3m)4.3%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)1.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.12
P/FCF N/A
P/OCF N/A
P/B 3.61
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.72
BVpS0.83
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.97%
ROE -61.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.3%
FCFM N/A
ROA(3y)-13.11%
ROA(5y)-4.04%
ROE(3y)-44.89%
ROE(5y)-7.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-39.06%
GM growth 5Y-23.95%
F-Score1
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.53%
Cap/Sales 7.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.6
Quick Ratio 5.69
Altman-Z 0.92
F-Score1
WACC11.07%
ROIC/WACCN/A
Cap/Depr(3y)84.26%
Cap/Depr(5y)73.34%
Cap/Sales(3y)13.93%
Cap/Sales(5y)9.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y33.57%
EPS Next 2Y21.89%
EPS Next 3Y18.43%
EPS Next 5Y7.77%
Revenue 1Y (TTM)-28.34%
Revenue growth 3Y-40.53%
Revenue growth 5Y-8.15%
Sales Q2Q%-11.83%
Revenue Next Year10.72%
Revenue Next 2Y9.3%
Revenue Next 3Y8.68%
Revenue Next 5Y8.13%
EBIT growth 1Y-82.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.49%
EBIT Next 3Y31.33%
EBIT Next 5Y19.21%
FCF growth 1Y-198.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-871.24%
OCF growth 3YN/A
OCF growth 5YN/A

MARAVAI LIFESCIENCES HLDGS-A / MRVI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRVI.


What is the valuation status for MRVI stock?

ChartMill assigns a valuation rating of 0 / 10 to MARAVAI LIFESCIENCES HLDGS-A (MRVI). This can be considered as Overvalued.


Can you provide the profitability details for MARAVAI LIFESCIENCES HLDGS-A?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a profitability rating of 1 / 10.


What is the expected EPS growth for MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?

The Earnings per Share (EPS) of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is expected to grow by 33.57% in the next year.